At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Phentolamine Ophthalmic Solution 0.75% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With Presbyopia
In Brief
A Phase 2 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, and 1 other intervention for Presbyopia. Completed, enrolled 150 participants across 17 sites.
Detailed Summary
The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionMay 2021
Study CompletionJun 2021
TodayJul 2026
First PostedDec 19, 2020
Enrollment StartFeb 15, 2021
Primary CompletionMay 17, 2021
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.5 years ago
Interventions
Phentolamine Ophthalmic Solution 0.75%drug
0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Pilocarpinedrug
Pilocarpine ophthalmic solution
Placeboother
Topical sterile ophthalmic solution